Antiangiogenic nanotherapy with lipase-labile Sn-2 fumagillin prodrug

Nanomedicine

Volumn 7, Issue 10, 2012, Pages 1507-1519

  Pan, Dipanjan ^a   Sanyal, Nibedita ^a   Schmieder, Anne H ^a   Senpan, Angana ^a   Kim, Benjamin ^a   Yang, Xiaoxia ^a   Hu, Grace ^a   Allen, John S ^a   Gross, Richard W ^a   Wickline, Samuel A ^a   Lanza, Gregory M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

angiogenesis; fumagillin; nanomedicine; nanoparticle; prodrug; therapy

Indexed keywords

FUMAGILLIN; MATRIGEL; NANOPARTICLE; PRODRUG; SN 2 LIPASE; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC NANOTHERAPY; ANTIANGIOGENIC THERAPY; ARTICLE; CELL METABOLISM; CELL PROLIFERATION; DRUG BIOAVAILABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NANOMEDICINE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTODEGRADATION; PRIORITY JOURNAL; RAT; THREE DIMENSIONAL IMAGING;

ANIMALS; BIOLOGICAL AVAILABILITY; CELLS, CULTURED; CYCLOHEXANES; FATTY ACIDS, UNSATURATED; HUMANS; LIPASE; MICE; NANOMEDICINE; NEOVASCULARIZATION, PATHOLOGIC; PRODRUGS; RATS; SESQUITERPENES;

EID: 84869461207     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.12.27     Document Type: Article

References (40)

1. Sin N, Meng L, Wang MQ, Wen JJ, Bornmann WG, Crews CM. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc. Natl Acad. Sci. USA 94(12), 6099-6103 (1997).
2. Liu S, Widom J, Kemp CW, Crews CM, Clardy J. Structure of human methionine aminopeptidase-2 complexed with fumagillin. Science 282(5392), 1324-1327 (1998).
3. Arfin SM, Kendall RL, Hall L et al. Eukaryotic methionyl aminopeptidases: two classes of cobalt-dependent enzymes. Proc. Natl Acad. Sci. USA 92(17), 7714-7718 (1995).
4. Wang J, Lou P, Henkin J. Selective inhibition of endothelial cell proliferation by fumagillin is not due to differential expression of methionine aminopeptidases. J. Cell. Biochem. 77(3), 465-473 (2000).
5. Lowther WT, Mcmillen DA, Orville AM, Matthews BW. The anti-angiogenic agent fumagillin covalently modifies a conserved active-site histidine in the Escherichia coli methionine aminopeptidase. Proc. Natl Acad. Sci. USA 95(21), 12153-12157 (1998).
6. Turk BE, Griffith EC, Wolf S, Biemann K, Chang YH, Liu JO. Selective inhibition of amino-terminal methionine processing by TNP-470 and ovalicin in endothelial cells. Chem. Biol. 6(11), 823-833 (1999).
7. Griffith EC, Su Z, Niwayama S, Ramsay CA, Chang YH, Liu JO. Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2. Proc. Natl Acad. Sci. USA 95(26), 15183-15188 (1998).
8. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284(5415), 808-812 (1999).
9. Castronovo V, Belotti D. TNP-470 (AGM-1470): mechanisms of action and early clinical development. Eur. J. Cancer 32A(14), 2520-2527 (1996).
10. Konno H, Tanaka T, Kanai T, Maruyama K, Nakamura S, Baba S. Efficacy of an angiogenesis inhibitor, TNP-470, in xenotransplanted human colorectal cancer with high metastatic potential. Cancer 77(8 Suppl), 1736-1740 (1996).
11. Shusterman S, Grupp SA, Barr R, Carpentieri D, Zhao H, Maris JM. The angiogenesis inhibitor TNP-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease. Clin. Cancer Res. 7(4), 977-984 (2001).
12. Bhargava P, Marshall JL, Rizvi N et al. A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin. Cancer Res. 5(8), 1989-1995 (1999).
13. Kudelka AP, Verschraegen CF, Loyer E. Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470. N. Engl. J. Med. 338(14), 991-992 (1998).
14. Logothetis CJ, Wu KK, Finn LD et al. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin. Cancer Res. 7(5), 1198-1203 (2001).
15. Offodile R, Walton T, Lee M, Stiles A, Nguyen M. Regression of metastatic breast cancer in a patient treated with the anti-angiogenic drug TNP-470. Tumori 85(1), 51-53 (1999).
16. Schmieder AH, Caruthers SD, Zhang H et al. Three-dimensional MR mapping of angiogenesis with {alpha}5{beta}1({alpha}{nu} {beta}3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model. FASEB J. 22, 4179-4189 (2008).
17. Wickline SA, Neubauer AM, Winter P, Caruthers S, Lanza G. Applications of nanotechnology to atherosclerosis, thrombosis, and vascular biology. Arterioscler. Thromb. Vasc. Biol. 26(3), 435-441 (2006).
18. Winter P, Caruthers S, Zhang H, Williams T, Wickline S, Lanza G. Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis. J. Am. Coll. Cardiol. Img. 1, 624-634 (2008).
19. Winter PM, Schmieder AH, Caruthers SD et al. Minute dosages of alpha(nu)beta3- targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits. FASEB J. 22, 2758-2767 (2008).
20. Lanza GM, Yu X, Winter PM et al. Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis. Circulation 106, 2842-2847 (2002).
21. Partlow K, Lanza G, Wickline S. Exploiting lipid raft transport with membrane targeted nanoparticles: a strategy for cytosolic drug delivery. Biomaterials 29, 3367-3375 (2008).
22. Soman N, Baldwin S, Hu G et al. A platform of molecularly targeted nanostructures for anticancer therapy with cytolytic peptides. J. Clin. Invest. 119, 2830-2842 (2009).
23. Winter P, Neubauer A, Caruthers S et al. Endothelial alpha(nu)beta(3)- integrin targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 26, 2103-2109 (2006).
24. Zhou HF, Chan HW, Wickline SA, Lanza GM, Pham CT. Alpha v beta 3-targeted nanotherapy suppresses inflammatory arthritis in mice. FASEB J. 23(9), 2978-2985 (2009).
25. Zhou HF, Hu G, Wickline SA, Lanza GM, Pham CT. Synergistic effect of antiangiogenic nanotherapy combined with methotrexate in the treatment of experimental inflammatory arthritis. Nanomedicine (Lond.) 5(7), 1065-1074 (2010).
26. Brahn E, Schoettler N, Lee S, Banquerigo ML. Involution of collagen-induced arthritis with an angiogenesis inhibitor, PPI-2458. J. Pharmacol. Exp. Ther. 329(2), 615-624 (2009).
27. Kochansky J, Nasr M. Laboratory studies on the photostability of fumagillin, the active ingredient of Fumidil B. Apidologie 35, 301-310 (2004).
28. Imhof BA, Aurrand-Lions M. Angiogenesis and inflammation face off. Nat. Med. 12(2), 171-172 (2006).
29. Arico-Muendel CC, Benjamin DR, Caiazzo TM et al. Carbamate analogues of fumagillin as potent, targeted inhibitors of methionine aminopeptidase-2. J. Med. Chem. 52 (24), 8047-8056 (2009).
30. Hu G, Lijowski M, Zhang H et al. Imaging of Vx-2 rabbit tumors with alpha(nu)beta3- integrin-targeted 111In nanoparticles. Int. J. Cancer 120, 1951-1957 (2007).
31. Burke J, Dennis E. Phospholipase A2 biochemistry. Cardiovasc. Drugs Ther. 23, 49-59 (2009).
32. Arik D, Duvdevani R, Shapiro I, Elmann A, Finkelstein E, Hoffman A. The oral absorption of phospholipid prodrugs: in vivo and in vitro mechanistic investigation of trafficking of a lecithin-valproic acid conjugate following oral administration. J. Control. Release 126, 1-9 (2008).
33. Dahan A, Duvdevani R, Dvir E, Elmann A, Hoffman A. A novel mechanism for oral controlled release of drugs by continuous degradation of a phospholipid prodrug along the intestine: in-vivo and in-vitro evaluation of an indomethacin-lecithin conjugate. J. Control. Release 119, 86-93 (2007).
34. Davidsen J, Jørgensen K, Andresen TL, Mouritsen OG. Secreted phospholipase A2 as a new enzymatic trigger mechanism for localised liposomal drug release and absorption in diseased tissue. Biochim. Biophys. Acta 1609(1), 95-101 (2003).
35. Andresen TL, Davidsen J, Begtrup M, Mouritsen OG, Jørgensen K. Enzymatic release of antitumor ether lipids by specific phospholipase A2 activation of liposome-forming prodrugs. J. Med. Chem. 47(7), 1694-1703 (2004).
36. Jensen SS, Andresen TL, Davidsen J et al. Secretory phospholipase A2 as tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids. Mol. Cancer Ther. 3(11), 1451-1458 (2004).
37. Andresen TL, Jensen SS, Kaasgaard T, Jørgensen K. Triggered activation and release of liposomal prodrugs and drugs in cancer tissue by secretory phospholipase A2. Curr. Drug Deliv. 2(4), 353-362 (2005).
38. Peters G, Møller M, Jørgensen K, Rönnholm P, Mikkelsen M, Andresen T. Secretory phospholipase A2 hydrolysis of phospholipid analogues is dependent on water accessibility to the active site. J. Am. Chem. Soc. 129(17), 5451-5461 (2007).
39. Garrett ER, Eble TE. Studies on the stability of fumagillin I. Photolytic degradation in alcohol solution. J. Am. Pharm. Assoc. 43(7), 385-390 (1954).
40. Zelphati O, Szoka FC. Intracellular distribution and mechanism of delivery of oligonucleotides mediated by cationic lipids. Pharm. Res. 13(9), 1367-1372 (1996).